NASDAQ:LYRA

Lyra Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy LYRA

*Your capital is at risk

$0.495

+0 (+0%)

At Close: Jun 03, 2026

Lyra Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 1.85. In total, the insiders bought 17.8M and sold 126.54K LYRA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	1.85
● Buy	17.8M shares
● Sell	126.54K shares
79% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Jun 01, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 14, 2025 Buy	Restricted Stock Units A-Award	Merrifield C Ann Director	Director	32 000 Value: $4K
May 14, 2025 Buy	Restricted Stock Units A-Award	Tobin James R Director	Director	32 000 Value: $4K
May 14, 2025 Buy	Restricted Stock Units A-Award	Snyderman Nancy Lynn Md Director	Director	32 000 Value: $4K
May 14, 2025 Buy	Restricted Stock Units A-Award	Smith W Bradford Director	Director	32 000 Value: $4K
May 14, 2025 Buy	Restricted Stock Units A-Award	Smith W Bradford Director	Director	32 000 Value: $4K
May 14, 2025 Buy	Restricted Stock Units A-Award	Snyderman Nancy Lynn Md Director	Director	32 000 Value: $4K
May 14, 2025 Buy	Restricted Stock Units A-Award	Tobin James R Director	Director	32 000 Value: $4K
May 14, 2025 Buy	Restricted Stock Units A-Award	Merrifield C Ann Director	Director	32 000 Value: $4K
Jan 08, 2025 Buy	Common Stock A-Award	Palasis Maria President & CEO	CEO / President	800 000 Value: $160.6K
Jan 08, 2025 Buy	Common Stock A-Award	Cavalier Jason Chief Financial Officer	C-Suite Officer	420 000 Value: $84.3K
Jan 08, 2025 Buy	Common Stock A-Award	Cavalier Jason Chief Financial Officer	C-Suite Officer	420 000 Value: $84.3K
Jan 08, 2025 Buy	Common Stock A-Award	Palasis Maria President & CEO	CEO / President	800 000 Value: $160.6K
Dec 09, 2024 Buy	Employee Stock Option (right to buy) A-Award	Palasis Maria President & CEO	CEO / President	183 333 Value: $1.11M
Dec 09, 2024 Buy	Performance-based Restricted Stock Units A-Award	Waksal Harlan Executive Chair	Officer	128 333 Value: $27.1K
Dec 09, 2024 Buy	Performance-based Restricted Stock Units A-Award	Waksal Harlan Executive Chair	Officer	128 333 Value: $27.1K
Dec 09, 2024 Buy	Employee Stock Option (right to buy) A-Award	Palasis Maria President & CEO	CEO / President	183 333 Value: $1.11M
Oct 16, 2024 Buy	Common Stock A-Award	Palasis Maria President & CEO	CEO / President	300 000 Value: $72.1K
Oct 16, 2024 Buy	Common Stock A-Award	Cavalier Jason Chief Financial Officer	C-Suite Officer	100 000 Value: $24.0K
Oct 16, 2024 Buy	Common Stock A-Award	Cavalier Jason Chief Financial Officer	C-Suite Officer	100 000 Value: $24.0K
Oct 16, 2024 Buy	Common Stock A-Award	Palasis Maria President & CEO	CEO / President	300 000 Value: $72.1K
Jun 13, 2024 Buy	Stock Option A-Award	Altman Michael Seth Director	Director	30 000 Value: $9K
Jun 13, 2024 Buy	Stock Option A-Award	Poukalov Konstantin Director	Director	30 000 Value: $9K
Jun 13, 2024 Buy	Stock Option A-Award	Tobin James R Director	Director	30 000 Value: $9K
Jun 13, 2024 Buy	Stock Option A-Award	Snyderman Nancy Lynn Md Director	Director	30 000 Value: $9K
Jun 13, 2024 Buy	Stock Option A-Award	Smith W Bradford Director	Director	30 000 Value: $9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LYRA THERAPEUTICS INC.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflam...

Read Full Profile Here